Ticker · CUSIP 478160104
Holders (tracked)
30
Combined shares
104,281,533
Combined value
$19.01B
Last close
$234.54
Quarter
2025Q4
Tracked holders · last 8 quarters
+3 vs previous quarter over the last 8.
Price is +28.6% vs the avg quarter-end implied price across tracked holders.
About
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
- CEO
- Joaquin Duato
- Employees
- 138,100
- Exchange
- NYSE
- Country
- US
- IPO
- 1943-01-02
- Website
- www.jnj.com
Key statistics
52W range84% of range
$146.12$251.71
- Market cap
- $564.35B
- Enterprise value
- $592.57B
- Shares out
- —
- Beta
- 0.33
- P/E (TTM)
- 27.22
- Div yield
- 2.22%
- 52W high
- $251.71
- 52W low
- $146.12
- 50D avg
- $241.32
- 200D avg
- $202.34
- Volume
- 8.83M
- Avg volume
- —
Valuation & profitability
TTM · FMP
Multiples
- P/E (TTM)
- 27.22
- PEG
- -1.24
- P/S
- 5.86
- P/B
- 7.02
- P/FCF
- 28.65
- EV/Sales
- 6.15
- EV/EBITDA
- 19.34
- EV/FCF
- 30.08
- Earnings yield
- 3.7%
- FCF yield
- 3.5%
Profitability
- Gross margin
- 73.9%
- EBITDA margin
- 31.8%
- Operating margin
- 26.7%
- Net margin
- 21.8%
Returns & leverage
- ROE
- 26.5%
- ROA
- 10.6%
- ROIC
- 14.1%
- Debt / equity
- 0.59
- Current ratio
- 1.03
Quarterly financials
Last 5Q
Revenue
$24.06B2026 Q1
Net income
$5.24B2026 Q1
Operating income
$6.39B2026 Q1
EPS (diluted)
$2.142026 Q1
Earnings surprise
EPS · Last 4Q
FY26 Q2 actual$2.70vs est $2.68+0.7%
EstimateActual (beat)Actual (miss)
Revenue segmentation
FMP · annual
By product line
FY2025$94.19B total
- Innovative Medicine$60.40B · 64.1%
- MedTech$33.79B · 35.9%
By geography
FY2025$94.19B total
- UNITED STATES$53.75B · 57.1%
- Europe$21.54B · 22.9%
- Asia-Pacific, Africa$14.03B · 14.9%
- Western Hemisphere, excluding U.S.$4.88B · 5.2%
SEC event timeline
30 events
- AQR Capital Management trimmed2026-02-17−450,231 shares · 2025Q413F
- Ken Griffin (Citadel Advisors) trimmed2026-02-17−545,257 shares · 2025Q413F
- D.E. Shaw & Co. trimmed2026-02-17−260,159 shares · 2025Q413F
- Wellington Management trimmed2026-02-17−2,594,389 shares · 2025Q413F
- +527,700 shares · 2025Q413F
- +3,600 shares · 2025Q413F
- Jeremy Grantham (GMO) added2026-02-17+273,944 shares · 2025Q413F
- Two Sigma Investments trimmed2026-02-17−894,928 shares · 2025Q413F
- Izzy Englander (Millennium Mgmt) added2026-02-17+299,951 shares · 2025Q413F
- Steve Cohen (Point72) added2026-02-17+113,215 shares · 2025Q413F
- T. Rowe Price added2026-02-17+3,655,754 shares · 2025Q413F
- John Rogers (Ariel Investments) trimmed2026-02-13−8,594 shares · 2025Q413F
- −401,819 shares · 2025Q413F
- Renaissance Technologies exited2026-02-12−306,747 shares · 2025Q413F
- Norges Bank (Norway SWF) opened position2026-02-10+33,459,884 shares · 2025Q413F
- Ken Fisher (Fisher Asset Mgmt) added2026-02-09+419,799 shares · 2025Q413F
- Mario Gabelli (GAMCO) trimmed2026-02-05−609 shares · 2025Q413F
- Izzy Englander (Millennium Mgmt) trimmed2025-11-14−424,060 shares · 2025Q313F
- Steve Cohen (Point72) trimmed2025-11-14−576,374 shares · 2025Q313F
- Two Sigma Investments added2025-11-14+748,295 shares · 2025Q313F
- D.E. Shaw & Co. trimmed2025-11-14−1,702,136 shares · 2025Q313F
- AQR Capital Management trimmed2025-11-14−469,037 shares · 2025Q313F
- T. Rowe Price added2025-11-14+390,599 shares · 2025Q313F
- Wellington Management added2025-11-14+956,239 shares · 2025Q313F
- John Rogers (Ariel Investments) added2025-11-14+20,691 shares · 2025Q313F
- Norges Bank (Norway SWF) exited2025-11-13−31,929,124 shares · 2025Q313F
- Jeremy Grantham (GMO) added2025-11-13+260,764 shares · 2025Q313F
- −566,762 shares · 2025Q313F
- Renaissance Technologies trimmed2025-11-13−576,443 shares · 2025Q313F
- Mario Gabelli (GAMCO) trimmed2025-11-12−4,207 shares · 2025Q313F
Insider activity
No insider transactions in the last 30 days.
Follow-the-investor returns
If you'd copied each holder of JNJ…
Cost basis inferred from 13F share-delta history. Sorted by % return on the position they're still holding.
| Investor | First in | Cost basis | Return | Position value today |
|---|---|---|---|---|
| T. Rowe Price | 2016Q1 | $58.56 | +300.5% | $2.91B |
| Tom Gayner (Markel Group) | 2016Q1 | $108.20 | +116.8% | $143.3M |
| Dodge & Cox | 2016Q1 | $109.94 | +113.3% | $4.9M |
| Prem Watsa (Fairfax Financial) | 2016Q1 | $111.37 | +110.6% | $17.2M |
| Mario Gabelli (GAMCO) | 2016Q1 | $116.26 | +101.7% | $19.2M |
| Wellington Management | 2016Q1 | $129.02 | +81.8% | $5.45B |
| Jeremy Grantham (GMO) | 2016Q1 | $134.00 | +75.0% | $1.66B |
| AQR Capital Management | 2016Q1 | $148.81 | +57.6% | $909.1M |
| John Rogers (Ariel Investments) | 2016Q1 | $150.26 | +56.1% | $10.1M |
| Ray Dalio (Bridgewater Associates) | 2016Q2 | $152.57 | +53.7% | $308.2M |
| Ken Fisher (Fisher Asset Mgmt) | 2016Q1 | $161.60 | +45.1% | $2.08B |
| Paul Tudor Jones (Tudor Investment) | 2016Q1 | $170.69 | +37.4% | $24.3M |
| Paul Tudor Jones (Tudor Investment) | 2016Q1 | $170.69 | +37.4% | $24.3M |
| Izzy Englander (Millennium Mgmt) | 2016Q1 | $180.18 | +30.2% | $167.1M |
| Izzy Englander (Millennium Mgmt) | 2016Q1 | $180.18 | +30.2% | $167.1M |
| Izzy Englander (Millennium Mgmt) | 2016Q1 | $180.18 | +30.2% | $167.1M |
| Two Sigma Investments | 2016Q1 | $188.16 | +24.6% | $8.9M |
| Two Sigma Investments | 2016Q1 | $188.16 | +24.6% | $8.9M |
| Two Sigma Investments | 2016Q1 | $188.16 | +24.6% | $8.9M |
| D.E. Shaw & Co. | 2016Q1 | $191.85 | +22.2% | $10.7M |
| D.E. Shaw & Co. | 2016Q1 | $191.85 | +22.2% | $10.7M |
| D.E. Shaw & Co. | 2016Q1 | $191.85 | +22.2% | $10.7M |
| Ken Griffin (Citadel Advisors) | 2016Q1 | $197.88 | +18.5% | $602.7M |
| Ken Griffin (Citadel Advisors) | 2016Q1 | $197.88 | +18.5% | $602.7M |
| Ken Griffin (Citadel Advisors) | 2016Q1 | $197.88 | +18.5% | $602.7M |
| Steve Cohen (Point72) | 2016Q4 | $206.22 | +13.7% | $43.1M |
| Steve Cohen (Point72) | 2016Q4 | $206.22 | +13.7% | $43.1M |
| Steve Cohen (Point72) | 2016Q4 | $206.22 | +13.7% | $43.1M |
| Ron Baron (Baron Capital / BAMCO) | 2025Q4 | $206.95 | +13.3% | $844K |
| Norges Bank (Norway SWF) | 2016Q1 | $527.36 | -55.5% | $7.85B |
Who moved on this name in 2025Q4
13F transactions reported for the latest quarter, grouped by direction.
New positions3
- Norges Bank (Norway SWF)+33,459,884$6.92B
- Paul Tudor Jones (Tudor Investment)+527,700$109.2M
- Ron Baron (Baron Capital / BAMCO)+3,600$745K
Added to5
- Ken Fisher (Fisher Asset Mgmt)+419,799$86.9M
- Izzy Englander (Millennium Mgmt)+299,951$62.1M
- Jeremy Grantham (GMO)+273,944$56.7M
- Steve Cohen (Point72)+113,215$23.4M
- T. Rowe Price+3,655,754$757K
Trimmed8
- Wellington Management−2,594,389$536.9M
- Two Sigma Investments−894,928$185.2M
- Ken Griffin (Citadel Advisors)−545,257$112.8M
- AQR Capital Management−450,231$93.2M
- Ray Dalio (Bridgewater Associates)−401,819$83.2M
- D.E. Shaw & Co.−260,159$53.8M
- John Rogers (Ariel Investments)−8,594$1.8M
- Mario Gabelli (GAMCO)−609$126K
Exited1
- Renaissance Technologies−306,747$56.9M
Institutional ownership over time
Distinct super-investors holding this ticker · combined dollar value, by quarter.
| Quarter | Holders | Combined value |
|---|---|---|
| 2022Q1 | 28 | $4.39T |
| 2022Q2 | 32 | $4.28T |
| 2022Q3 | 31 | $4.06B |
| 2022Q4 | 30 | $48.33B |
| 2023Q1 | 32 | $44.49B |
| 2023Q2 | 30 | $46.80B |
| 2023Q3 | 30 | $37.52B |
| 2023Q4 | 25 | $37.35B |
| 2024Q1 | 25 | $42.70B |
| 2024Q2 | 29 | $41.64B |
| 2024Q3 | 25 | $13.18B |
| 2024Q4 | 28 | $9.08B |
| 2025Q1 | 26 | $9.68B |
| 2025Q2 | 28 | $14.42B |
| 2025Q3 | 27 | $11.39B |
| 2025Q4 | 30 | $19.01B |
Congress members trading this stock
| Date | Member | Type | Amount range | Filing |
|---|---|---|---|---|
| 2026-03-26 | Thomas H. Kean | Sell (P) | $1K – $15K | PDF ↗ |
| 2026-03-19 | John Boozman | Sell (P) | $1K – $15K | PDF ↗ |
| 2026-03-19 | Richard Dean Dr McCormick | Sell (P) | $1K – $15K | PDF ↗ |
| 2026-03-19 | Richard Dean Dr McCormick | Sell (P) | $1K – $15K | PDF ↗ |
| 2026-03-10 | Lloyd Doggett | Buy | $1K – $15K | PDF ↗ |
| 2025-12-18 | Julie Johnson | Sell | $1K – $15K | PDF ↗ |
| 2025-12-09 | Lloyd Doggett | Buy | $1K – $15K | PDF ↗ |
| 2025-11-13 | Julie Johnson | Sell (P) | $1K – $15K | PDF ↗ |
| 2025-11-05 | Richard Dean Dr McCormick | Buy | $1K – $15K | PDF ↗ |
| 2025-10-31 | Lisa McClain | Sell | $1K – $15K | PDF ↗ |
| 2025-10-30 | Lisa McClain | Buy | $1K – $15K | PDF ↗ |
| 2025-10-30 | Lisa McClain | Sell | $1K – $15K | PDF ↗ |
Who owns JNJ
30 super-investors · 2025Q4
Tracked stake
104.28M
shares
Combined value
$19.01B
% of shares outstanding
4.33%
tracked institutions only
Quarter action mix
New4Added9Trim14Held3
| # | Manager | Shares | Value |
|---|---|---|---|
| 1 | Norges Bank Norway SWF | 33.46M | $6.92B |
| 2 | Wellington Management | 23.24M | $4.81B |
| 3 | Ken Fisher Fisher Asset Mgmt | 8.87M | $1.83B |
| 4 | Jeremy Grantham GMO | 7.09M | $1.47B |
| 5 | AQR Capital Management | 3.88M | $802M |
| 6 | Ken Griffin Citadel Advisors | 3.07M | $636M |
| 7 | Ken Griffin Citadel Advisors | 2.57M | $532M |
| 8 | Izzy Englander Millennium Mgmt | 1.56M | $322M |
| 9 | Ray Dalio Bridgewater Associates | 1.31M | $272M |
| 10 | Izzy Englander Millennium Mgmt | 928.6K | $192M |
| 11 | Steve Cohen Point72 | 897.6K | $186M |
| 12 | D.E. Shaw & Co. | 883.5K | $183M |
| 13 | D.E. Shaw & Co. | 799.6K | $165M |
| 14 | Ken Griffin Citadel Advisors | 784.9K | $162M |
| 15 | Izzy Englander Millennium Mgmt | 712.4K | $147M |
| 16 | Tom Gayner Markel Group | 610.8K | $126M |
| 17 | Paul Tudor Jones Tudor Investment | 424.1K | $88M |
| 18 | Steve Cohen Point72 | 183.7K | $38M |
| 19 | Steve Cohen Point72 | 120.6K | $25M |
| 20 | Paul Tudor Jones Tudor Investment | 103.6K | $21M |
| 21 | Mario Gabelli GAMCO | 81.8K | $17M |
| 22 | Prem Watsa Fairfax Financial | 73.4K | $15M |
| 23 | D.E. Shaw & Co. | 45.7K | $9M |
| 24 | John Rogers Ariel Investments | 43.3K | $9M |
| 25 | Two Sigma Investments | 38.1K | $8M |
| 26 | Two Sigma Investments | 30.4K | $6M |
| 27 | Two Sigma Investments | 27.2K | $6M |
| 28 | Dodge & Cox | 20.9K | $4M |
| 29 | T. Rowe Price | 12.42M | $3M |
| 30 | Ron Baron Baron Capital / BAMCO | 3.6K | $745K |
Recent moves
20 transactions
- +3,600 · 2025Q4
- +3,655,754 · 2025Q4
- +113,215 · 2025Q4
- +273,944 · 2025Q4
- TRIMD.E. Shaw & Co.−260,159 · 2025Q4
- −2,594,389 · 2025Q4
- −545,257 · 2025Q4
- −450,231 · 2025Q4
- −894,928 · 2025Q4
- +527,700 · 2025Q4
- +299,951 · 2025Q4
- −401,819 · 2025Q4
- −8,594 · 2025Q4
- −306,747 · 2025Q4
- +33,459,884 · 2025Q4
- +419,799 · 2025Q4
- −609 · 2025Q4
- −424,060 · 2025Q3
- −576,374 · 2025Q3
- +748,295 · 2025Q3
Embed this chart
Paste this iframe anywhere to embed the live JNJ chart.
<iframe src="https://openstocks.me/embed/stock/JNJ" width="100%" height="480" frameborder="0" loading="lazy" title="JNJ chart by OpenStocks" style="border:0;border-radius:12px;background:transparent"></iframe>